Trials / Terminated
TerminatedNCT01499043
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
A Pilot Study of PLX3397 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastasis and High Circulating Tumor Cell (CTC) Counts
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 6 (actual)
- Sponsor
- Daiichi Sankyo · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the the subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PLX3397 | Capsules administered twice daily, continuous dosing. Subjects will take PLX3397 at 1000 mg/day. |
Timeline
- Start date
- 2012-05-25
- Primary completion
- 2013-03-11
- Completion
- 2013-03-11
- First posted
- 2011-12-26
- Last updated
- 2020-03-04
- Results posted
- 2019-10-18
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01499043. Inclusion in this directory is not an endorsement.